Pulmonary Arterial Hypertension
📧 Sign up to get email alerts when something new happens for Pulmonary Arterial Hypertension.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2024-10-18Clinical Trial Update: Pulmonary Artery Denervation for Treatment of Pulmonary Arterial Hypertension [NA]
This update reports the termination of a clinical trial evaluating pulmonary artery denervation as a treatment for pulmonary arterial hypert…
-
CLINICAL_TRIALS trial_result · 2024-10-16Clinical Trial Update: Interventions Against Insulin Resistance in Pulmonary Arterial Hypertension [Phase 2]
Phase 2 trial update from Vanderbilt University Medical Center evaluating interventions targeting insulin resistance in patients with pulmon…
-
CLINICAL_TRIALS trial_result · 2024-10-16Clinical Trial Update: Safety, Tolerability and Pharmacokinetics of L608 in Healthy Adults [Phase 1]
This Phase 1 trial reports on the safety, tolerability and pharmacokinetics of L608 in healthy adults.
-
CLINICAL_TRIALS trial_result · 2024-10-15Clinical Trial Update: Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH (Zamicastat) [Phase 2]
Phase 2 trial assessing pharmacokinetics, safety, and efficacy of Zamicastat (BIA 5-1058) in pulmonary arterial hypertension; study complete…
-
CLINICAL_TRIALS research · 2024-10-15Clinical Trial Update: Quantifying 18kDa TSPO Expression in the Lung in Pulmonary Artery Hypertension (PAH)
Imperial College London is conducting a study to quantify 18kDa TSPO expression in the lungs of people with Pulmonary Arterial Hypertension …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-10-10Clinical Trial Update: Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL) [Phase 3]
The Phase 3 IMPAHCT-FUL trial evaluating inhaled imatinib for pulmonary arterial hypertension was terminated. Results have been posted.
-
CLINICAL_TRIALS trial_result · 2024-10-04Clinical Trial Update: Effect of CS1 in Subjects With Pulmonary Arterial Hypertension [Phase 2]
A Phase 2 clinical trial evaluating CS1 in pulmonary arterial hypertension has completed.
-
CLINICAL_TRIALS trial_result · 2024-09-23Clinical Trial Update: Subcutaneous Treprostinil as a Bridge to Lung Transplantation in Severe Pulmonary Hypertension: A Single-Arm Retrospective Study [Phase 4]
Phase 4 single-arm retrospective study assessing subcutaneous treprostinil as a bridge to lung transplantation in patients with severe pulmo…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Bioequivalence Study of Macitentan and Tadalafil Film-coated Tablets 10 Mg/40 Mg and 'PrOpsynvi®' Macitentan and Tadalafil Film-coated Tablets 10 Mg/40 Mg [Phase 1]
Phase 1 bioequivalence study of Macitentan and Tadalafil 10 mg/40 mg film-coated tablets (PrOpsynvi) has completed, assessing equivalence fo…
-
CLINICAL_TRIALS research · 2024-09-19Clinical Trial Update: the Application of Cardiopulmonary Exercise Testing in Assessment Outcome of Patients With Pulmonary Hypertension
A clinical trial update indicates a study evaluating the use of cardiopulmonary exercise testing to assess outcomes in patients with pulmona…
-
FDA approval · 2024-09-17FDA Approved: TRACLEER — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
FDA approved a supplemental application for TRACLEER (bosentan) from Actelion Pharmaceuticals US, Inc.
-
FDA approval · 2024-09-17FDA Approved: TRACLEER — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
The FDA approved a supplemental application for Tracleer (bosentan) submitted by Actelion Pharmaceuticals US, Inc., authorizing changes to t…
-
FDA approval · 2024-09-17FDA Approved: BOSENTAN — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for bosentan filed by Actavis Pharma, Inc. to authorize the continued marketing of the generic produ…
-
FDA approval · 2024-09-17FDA Approved: BOSENTAN — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Bosentan from Zydus Pharmaceuticals USA Inc. under ANDA207760. This confirms continued regulator…
-
FDA approval · 2024-09-17FDA Approved: BOSENTAN — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for BOSENTAN from Sun Pharmaceutical Industries, enabling the generic bosentan to be marketed in the…
-
CLINICAL_TRIALS trial_result · 2024-09-03Clinical Trial Update: Efficacy and Safety of High-Flow Nasal Cannula Versus Noninvasive Ventilation for Pulmonary Arterial Hypertension-Associated Acute Respiratory Failure
This clinical trial update describes a comparison of high-flow nasal cannula versus noninvasive ventilation for patients with pulmonary arte…
-
CLINICAL_TRIALS research · 2024-08-28Clinical Trial Update: Myocardial Work Evaluation in Patients With PAH
This clinical trial update indicates a study evaluating myocardial work in patients with pulmonary arterial hypertension is currently recrui…
-
CLINICAL_TRIALS trial_result · 2024-08-23Clinical Trial Update: A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH) [Phase 2, Phase 3]
AAV-101 (Dry Powder Inhaled Imatinib) trial for pulmonary arterial hypertension (Phase 2/3) funded by Aerovate Therapeutics has been termina…
-
CLINICAL_TRIALS trial_result · 2024-08-20Clinical Trial Update: A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging [Phase 4]
Phase 4 trial of Selexipag in pulmonary arterial hypertension was terminated; results were posted, assessing right ventricular remodeling vi…
-
FDA approval · 2024-08-19FDA Approved: AMBRISENTAN — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for Ambrisentan from Mylan Pharmaceuticals Inc., approving a generic version of the drug used to tre…
-
FDA label_change · 2024-08-19FDA Approved: LETAIRIS — Supplemental Application (Gilead Sciences, Inc.)
FDA approved a supplemental application for LETAIRIS (ambrisentan) from Gilead Sciences, resulting in changes to the drug's labeling.
-
FDA approval · 2024-08-19FDA Approved: AMBRISENTAN — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for Ambrisentan submitted by Apotex Corp., marking an additional regulatory action for this medicati…
-
FDA approval · 2024-08-19FDA Approved: AMBRISENTAN — Supplemental Application (Cipla USA Inc.)
FDA approved Cipla USA Inc.'s supplemental application for ambrisentan (ANDA 210715).
-
FDA approval · 2024-08-19FDA Approved: AMBRISENTAN — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for ambrisentan submitted by Zydus Lifesciences Limited. The drug is used to treat pulmonary arteria…
-
FDA approval · 2024-08-19FDA Approved: AMBRISENTAN — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical Industries' supplemental application to market a generic version of ambrisentan for pulmonary arterial hyper…